Molecular Vision: Sodi, Mol Vis 2012; 18:2736-2748. Table 2

Table 2. Clinical details of the VMD patients included in the study (families H-S).

Family	Family Member	Sex	Age (years)	Onset (years)	BCVA OD	BCVA OS	Fundus OD	Fundus OS	Notes
H	I-1	M	63	53	0.4	0.8	VR	PH	MultRE
H	II-1	M	34	//	1.0	1.0	Norm	Norm
H	II-2	F	27	//	1.0	1.0	Norm	Norm
I	II-1	M	22	2	0.3	0.7	FI	FI
I	I-1	M	60	30	0.8	1.0	VL	VL	MultOU
I	II-2	F	20	//	1.0	1.0	Norm	Norm
J	III-1	F	15	5	0.4	0.8	FI	FI	CNV; P
J	II-2	M	46	6	0.5	0.5	VR	VR
J	II-3	M	52	10	0.7	0.3	FI	FI
J	I-1	M	82	50	0.8	0.1	AT	AT
K	I-2	F	45	33	0.3	0.7	FI	VR	CNV; P; A
K	II-1	M	16	7	0.2	0.9	FI	PH	CNV;P
K	I-3	F	40	//	1.0	1.0	Norm	Norm
K	II-2	M	21	//	0.6	0.6	Norm	Norm	Cong Ny
K	II-3	F	19	//	1.0	1.0	Norm	Norm
L	II-1	M	45	15	0.4	0.6	PH	VR
M	II-1	F	38	25	0.3	0.5	VR	VR
N	III-1	M	35	25	1.0	0.9	PH	VR
N	II-3	M	47	35	0.2	1.0	AT	PH
O	II-1	F	48	35	0.1	0.1	VR	VR
P	II-1	F	62	47	0.5	0.6	VR	PH
Q	I-2	F	72	60	0.2	0.5	AT	VL
Q	II-1	F	44	//	1.0	1.0	Norm	Norm
R	II-1	F	41	37	0.6	0.9	VR	VL
S	II-1	M	32	25	0.8	1.0	AT	AT

For each patient the stage of disease is indicated. (BCVA: Best Corrected Visual Acuity; VL: vitelliform lesion; PH: pseudohypopyon stage; VR: vitelliruptive stage; AT: atrophic stage; FI: fibrotic stage; CNV: previous choroidal neovascularization; P: treated with photodynamic therapy; A: treated with intravitreal bevacizumab; Mult: multifocal presentation of the disease; Cong Ny: congenital nystagmus; OD: right eye; OS: left eye; //: unknown; OU: both eyes).